Clinical Trials Browser

Interventional × Vascular Endothelial Growth Factor A × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT07346157 2026-01-16

PNOC044

Phase 1/2 Not yet recruiting

69 enrolled

CNS

Medulloblastoma

NCT01871766 2025-12-17

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Phase 2 Active not recruiting

115 enrolled

Sarcoma

Rhabdomyosarcoma

NCT01551745 2021-10-19

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Phase 2 Completed

5 enrolled 9 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01767792 2021-02-12

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Phase 2 Completed

22 enrolled 14 charts

CNS

Neurofibromatosis 2

NCT00483834 2019-02-15

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Phase 2 Completed

50 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00288015 2018-06-25

Bevacizumab in Treating Patients With Angiosarcoma

Phase 2 Completed

32 enrolled 12 charts

Sarcoma

Hemangiosarcoma, Sarcoma

Clinical Trials

LuCa-MERIT-1

PNOC044

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Bevacizumab in Treating Patients With Angiosarcoma